Figure S1 from A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer

Authors :: Sarah P. Blagden
David J. Harrison
Nigel W. McCracken
Essam Ghazaly
Hani Gabra
Ajithkumar Sukumaran
Chat Gnanaranjan
Laura Spiers
Rene L. Roux
Shibani Nicum
Farasat Kazmi
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Scheme of base PK model for NUC-1031, dFdC and dFdU

Full Text Access

Tools